Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oregovomab - OncoQuest

Next Previous
Drug Profile

Oregovomab - OncoQuest

Alternative Names: Anti-CA125-monoclonal-antibody-B43-13-AltaRex; Anti-idiotype-ovarian-cancer-vaccine-AltaRex; Anti-idiotype-ovarian-cancer-vaccine-CA125; Mab B43.13; Monoclonal antibody B43.13; OvaRex; Ovarian-cancer-vaccine-AltaRex

Latest Information Update: 27 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AltaRex
  • Developer National Cancer Centre (Singapore); National Cancer Institute (USA); OncoQuest; University of Nebraska Medical Center
  • Class Cancer vaccines; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ovarian cancer; Pancreatic cancer
  • Phase I/II Peritoneal cancer

Most Recent Events

  • 27 Sep 2019 OncoQuest in collaboration with TESARO initiates a phase I/II trial of oregovomab for Ovarian cancer (Combination therapy) (OncoQuest pipeline, September 2019)
  • 25 Sep 2019 OncoQuest receives patent allowance for oregovomab in USA
  • 25 Sep 2019 OncoQuest plans a phase III trial for Ovarian cancer (Newly diagnosed, Late-stage disease) in Q1 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top